<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35453505</PMID><DateRevised><Year>2024</Year><Month>08</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2227-9059</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Mar</Month><Day>23</Day></PubDate></JournalIssue><Title>Biomedicines</Title><ISOAbbreviation>Biomedicines</ISOAbbreviation></Journal><ArticleTitle>PI3K Signaling in Mechanisms and Treatments of Pulmonary Fibrosis Following Sepsis and Acute Lung Injury.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">756</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biomedicines10040756</ELocationID><Abstract><AbstractText>Pulmonary fibrosis is a pathological fibrotic process affecting the lungs of five million people worldwide. The incidence rate will increase even more in the next years due to the long-COVID-19 syndrome, but a resolving treatment is not available yet and usually prognosis is poor. The emerging role of the phosphatidylinositol 3-kinase (PI3K)/AKT signaling in fibrotic processes has inspired the testing of drugs targeting the PI3K/Akt pathway that are currently under clinical evaluation. This review highlights the progress in understanding the role of PI3K/Akt in the development of lung fibrosis and its causative pathological context, including sepsis as well as acute lung injury (ALI) and its consequent acute respiratory distress syndrome (ARDS). We further summarize current knowledge about PI3K inhibitors for pulmonary fibrosis treatment, including drugs under development as well as in clinical trials. We finally discuss how the design of inhaled compounds targeting the PI3K pathways might potentiate efficacy and improve tolerability.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Margaria</LastName><ForeName>Jean Piero</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Via Nizza 52, 10126 Torino, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moretta</LastName><ForeName>Lucia</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-1920-6749</Identifier><AffiliationInfo><Affiliation>Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Via Nizza 52, 10126 Torino, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alves-Filho</LastName><ForeName>Jose Carlos</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0002-9918-8714</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology, Ribeir&#xe3;o Preto Medical School, University of S&#xe3;o Paulo, Avenida Bandeirantes 3900, Ribeirao Preto 14049-900, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirsch</LastName><ForeName>Emilio</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-9073-6024</Identifier><AffiliationInfo><Affiliation>Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Via Nizza 52, 10126 Torino, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomedicines</MedlineTA><NlmUniqueID>101691304</NlmUniqueID><ISSNLinking>2227-9059</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ARDS</Keyword><Keyword MajorTopicYN="N">PI3K</Keyword><Keyword MajorTopicYN="N">inhibitor</Keyword><Keyword MajorTopicYN="N">pulmonary fibrosis</Keyword><Keyword MajorTopicYN="N">sepsis</Keyword></KeywordList><CoiStatement>Emilio Hirsch is co-founder of Kither Biotech, a company involved in the development of PI3K inhibitors. The other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>23</Day><Hour>1</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>3</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35453505</ArticleId><ArticleId IdType="pmc">PMC9028704</ArticleId><ArticleId IdType="doi">10.3390/biomedicines10040756</ArticleId><ArticleId IdType="pii">biomedicines10040756</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wynn T.A. Integrating mechanisms of pulmonary fibrosis. J. Exp. Med. 2011;208:1339&#x2013;1350. doi: 10.1084/jem.20110551.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20110551</ArticleId><ArticleId IdType="pmc">PMC3136685</ArticleId><ArticleId IdType="pubmed">21727191</ArticleId></ArticleIdList></Reference><Reference><Citation>Lederer D.J., Martinez F.J. Idiopathic Pulmonary Fibrosis. N. Engl. J. Med. 2018;378:1811&#x2013;1823. doi: 10.1056/NEJMra1705751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1705751</ArticleId><ArticleId IdType="pubmed">29742380</ArticleId></ArticleIdList></Reference><Reference><Citation>Meltzer E.B., Noble P.W. Idiopathic pulmonary fibrosis. Orphanet J. Rare Dis. 2008;3:8. doi: 10.1186/1750-1172-3-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1172-3-8</ArticleId><ArticleId IdType="pmc">PMC2330030</ArticleId><ArticleId IdType="pubmed">18366757</ArticleId></ArticleIdList></Reference><Reference><Citation>Chousterman B.G., Swirski F.K., Weber G.F. Cytokine storm and sepsis disease pathogenesis. Semin. Immunopathol. 2017;39:517&#x2013;528. doi: 10.1007/s00281-017-0639-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-017-0639-8</ArticleId><ArticleId IdType="pubmed">28555385</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandrasekaran S., Funk C.R., Kleber T., Paulos C.M., Shanmugam M., Waller E.K. Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-&#x3b4; and -&#x3b3;. Front. Immunol. 2021;12:718621. doi: 10.3389/fimmu.2021.718621.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.718621</ArticleId><ArticleId IdType="pmc">PMC8427697</ArticleId><ArticleId IdType="pubmed">34512641</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkins P.T., Stephens L.R. PI3K signalling in inflammation. Biochim. Biophys. Acta. 2015;1851:882&#x2013;897. doi: 10.1016/j.bbalip.2014.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbalip.2014.12.006</ArticleId><ArticleId IdType="pubmed">25514767</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito S., Zhuang Y., Shan B., Danchuk S., Luo F., Korfei M., Guenther A., Lasky J.A. Tubastatin ameliorates pulmonary fibrosis by targeting the TGF&#x3b2;-PI3K-Akt pathway. PLoS ONE. 2017;12:e0186615. doi: 10.1371/journal.pone.0186615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0186615</ArticleId><ArticleId IdType="pmc">PMC5646855</ArticleId><ArticleId IdType="pubmed">29045477</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang L., Chen H., Kong R., Que J. Endogenous tryptophan metabolite 5-Methoxytryptophan inhibits pulmonary fibrosis by downregulating the TGF-&#x3b2;/SMAD3 and PI3K/AKT signaling pathway. Life Sci. 2020;260:118399. doi: 10.1016/j.lfs.2020.118399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.118399</ArticleId><ArticleId IdType="pubmed">32918977</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang E., Peng N., Xiao F., Hu D., Wang X., Lu L. The Roles of Immune Cells in the Pathogenesis of Fibrosis. Int. J. Mol. Sci. 2020;21:5203. doi: 10.3390/ijms21155203.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21155203</ArticleId><ArticleId IdType="pmc">PMC7432671</ArticleId><ArticleId IdType="pubmed">32708044</ArticleId></ArticleIdList></Reference><Reference><Citation>Fink M.P. Animal models of sepsis. Virulence. 2014;5:143&#x2013;153. doi: 10.4161/viru.26083.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/viru.26083</ArticleId><ArticleId IdType="pmc">PMC3916368</ArticleId><ArticleId IdType="pubmed">24022070</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan P., Tan X., Xiang Y., Tong H., Yu M. PI3K/AKT and CD40L Signaling Regulate Platelet Activation and Endothelial Cell Damage in Sepsis. Inflammation. 2018;41:1815&#x2013;1824. doi: 10.1007/s10753-018-0824-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-018-0824-5</ArticleId><ArticleId IdType="pubmed">29956071</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X., Xu Q., Wan H., Hu Y., Xing S., Yang H., Gao Y., He Z. PI3K-Akt-mTOR/PFKFB3 pathway mediated lung fibroblast aerobic glycolysis and collagen synthesis in lipopolysaccharide-induced pulmonary fibrosis. Lab. Investig. 2020;100:801&#x2013;811. doi: 10.1038/s41374-020-0404-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41374-020-0404-9</ArticleId><ArticleId IdType="pubmed">32051533</ArticleId></ArticleIdList></Reference><Reference><Citation>Kindrachuk J., Ork B., Hart B.J., Mazur S., Holbrook M.R., Frieman M.B., Traynor D., Johnson R.F., Dyall J., Kuhn J.H., et al. Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis. Antimicrob. Agents Chemother. 2015;59:1088&#x2013;1099. doi: 10.1128/AAC.03659-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.03659-14</ArticleId><ArticleId IdType="pmc">PMC4335870</ArticleId><ArticleId IdType="pubmed">25487801</ArticleId></ArticleIdList></Reference><Reference><Citation>Acharya A., Pandey K., Thurman M., Challagundala K.B., Vann K.R., Kutateladze T.G., Morales G.A., Durden D.L., Byrareddy S.N. Blockade of SARS-CoV-2 infection in vitro by highly potent PI3K-&#x3b1;/mTOR/BRD4 inhibitor. bioRxiv. 2021 doi: 10.1101/2021.03.02.433604.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.02.433604</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Teijaro J.R. Cytokine storms in infectious diseases. Semin. Immunopathol. 2017;39:501&#x2013;503. doi: 10.1007/s00281-017-0640-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-017-0640-2</ArticleId><ArticleId IdType="pmc">PMC7079934</ArticleId><ArticleId IdType="pubmed">28674818</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrey A.C., Qeadan F., Middleton E.A., Pinchuk I.V., Campbell R.A., Beswick E.J. Cytokine release syndrome in COVID-19: Innate immune, vascular, and platelet pathogenic factors differ in severity of disease and sex. J. Leukoc. Biol. 2021;109:55&#x2013;66. doi: 10.1002/JLB.3COVA0820-410RRR.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JLB.3COVA0820-410RRR</ArticleId><ArticleId IdType="pmc">PMC7902354</ArticleId><ArticleId IdType="pubmed">32930456</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S.S., Chauhan S.B., Kumar A., Kumar S., Engwerda C.R., Sundar S., Kumar R. Amphiregulin in cellular physiology, health, and disease: Potential use as a biomarker and therapeutic target. J. Cell. Physiol. 2022;237:1143&#x2013;1156. doi: 10.1002/jcp.30615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.30615</ArticleId><ArticleId IdType="pubmed">34698381</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthay M.A., Zemans R.L., Zimmerman G.A., Arabi Y.M., Beitler J.R., Mercat A., Herridge M., Randolph A.G., Calfee C.S. Acute respiratory distress syndrome. Nat. Rev. Dis. Primers. 2019;5:18. doi: 10.1038/s41572-019-0069-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-019-0069-0</ArticleId><ArticleId IdType="pmc">PMC6709677</ArticleId><ArticleId IdType="pubmed">30872586</ArticleId></ArticleIdList></Reference><Reference><Citation>Sessler C.N., Bloomfield G.L., Fowler A.A. Current concepts of sepsis and acute lung injury. Clin. Chest Med. 1996;17:213&#x2013;235. doi: 10.1016/S0272-5231(05)70310-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0272-5231(05)70310-5</ArticleId><ArticleId IdType="pubmed">8792062</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranieri V.M., Rubenfeld G.D., Thompson B.T., Ferguson N.D., Caldwell E., Fan E., Camporota L., Slutsky A.S., Force A.D.T. Acute respiratory distress syndrome: The Berlin Definition. JAMA. 2012;307:2526&#x2013;2533. doi: 10.1001/jama.2012.5669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2012.5669</ArticleId><ArticleId IdType="pubmed">22797452</ArticleId></ArticleIdList></Reference><Reference><Citation>Meduri G.U., Eltorky M., Winer-Muram H.T. The fibroproliferative phase of late adult respiratory distress syndrome. Semin. Respir. Infect. 1995;10:154&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">7481129</ArticleId></ArticleIdList></Reference><Reference><Citation>Ourradi K., Blythe T., Jarrett C., Barratt S.L., Welsh G.I., Millar A.B. VEGF isoforms have differential effects on permeability of human pulmonary microvascular endothelial cells. Respir. Res. 2017;18:116. doi: 10.1186/s12931-017-0602-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-017-0602-1</ArticleId><ArticleId IdType="pmc">PMC5457598</ArticleId><ArticleId IdType="pubmed">28578669</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchetti L., Klein M., Schlett K., Pfizenmaier K., Eisel U.L. Tumor necrosis factor (TNF)-mediated neuroprotection against glutamate-induced excitotoxicity is enhanced by N-methyl-D-aspartate receptor activation. Essential role of a TNF receptor 2-mediated phosphatidylinositol 3-kinase-dependent NF-kappa B pathway. J. Biol. Chem. 2004;279:32869&#x2013;32881. doi: 10.1074/jbc.M311766200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M311766200</ArticleId><ArticleId IdType="pubmed">15155767</ArticleId></ArticleIdList></Reference><Reference><Citation>Vecchione C., Patrucco E., Marino G., Barberis L., Poulet R., Aretini A., Maffei A., Gentile M.T., Storto M., Azzolino O., et al. Protection from angiotensin II-mediated vasculotoxic and hypertensive response in mice lacking PI3Kgamma. J. Exp. Med. 2005;201:1217&#x2013;1228. doi: 10.1084/jem.20040995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20040995</ArticleId><ArticleId IdType="pmc">PMC2213159</ArticleId><ArticleId IdType="pubmed">15824082</ArticleId></ArticleIdList></Reference><Reference><Citation>Yudowski G.A., Efendiev R., Pedemonte C.H., Katz A.I., Berggren P.O., Bertorello A.M. Phosphoinositide-3 kinase binds to a proline-rich motif in the Na+, K+-ATPase alpha subunit and regulates its trafficking. Proc. Natl. Acad. Sci. USA. 2000;97:6556&#x2013;6561. doi: 10.1073/pnas.100128297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.100128297</ArticleId><ArticleId IdType="pmc">PMC18657</ArticleId><ArticleId IdType="pubmed">10823893</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin C.H., Cheng H.W., Ma H.P., Wu C.H., Hong C.Y., Chen B.C. Thrombin induces NF-kappaB activation and IL-8/CXCL8 expression in lung epithelial cells by a Rac1-dependent PI3K/Akt pathway. J. Biol. Chem. 2011;286:10483&#x2013;10494. doi: 10.1074/jbc.M110.112433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.112433</ArticleId><ArticleId IdType="pmc">PMC3060502</ArticleId><ArticleId IdType="pubmed">21266580</ArticleId></ArticleIdList></Reference><Reference><Citation>Michalski J.E., Kurche J.S., Schwartz D.A. From ARDS to pulmonary fibrosis: The next phase of the COVID-19 pandemic? Transl. Res. 2022;241:13&#x2013;24. doi: 10.1016/j.trsl.2021.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2021.09.001</ArticleId><ArticleId IdType="pmc">PMC8452088</ArticleId><ArticleId IdType="pubmed">34547499</ArticleId></ArticleIdList></Reference><Reference><Citation>Mo X., Jian W., Su Z., Chen M., Peng H., Peng P., Lei C., Chen R., Zhong N., Li S. Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. Eur. Respir. J. 2020;55:2001217. doi: 10.1183/13993003.01217-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01217-2020</ArticleId><ArticleId IdType="pmc">PMC7236826</ArticleId><ArticleId IdType="pubmed">32381497</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T., Sun L.X., Feng R.E. Comparison of clinical and pathological features between severe acute respiratory syndrome and coronavirus disease 2019. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43:496&#x2013;502. doi: 10.3760/cma.j.cn112147-20200311-00312.</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.cn112147-20200311-00312</ArticleId><ArticleId IdType="pubmed">32241072</ArticleId></ArticleIdList></Reference><Reference><Citation>Conte E., Fruciano M., Fagone E., Gili E., Caraci F., Iemmolo M., Crimi N., Vancheri C. Inhibition of PI3K prevents the proliferation and differentiation of human lung fibroblasts into myofibroblasts: The role of class I P110 isoforms. PLoS ONE. 2011;6:e24663. doi: 10.1371/journal.pone.0024663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0024663</ArticleId><ArticleId IdType="pmc">PMC3184941</ArticleId><ArticleId IdType="pubmed">21984893</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder L.S., Hertz M.I., Peterson M.S., Harmon K.R., Marinelli W.A., Henke C.A., Greenheck J.R., Chen B., Bitterman P.B. Acute lung injury. Pathogenesis of intraalveolar fibrosis. J. Clin. Investig. 1991;88:663&#x2013;673. doi: 10.1172/JCI115351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI115351</ArticleId><ArticleId IdType="pmc">PMC295409</ArticleId><ArticleId IdType="pubmed">1864975</ArticleId></ArticleIdList></Reference><Reference><Citation>De Santis M.C., Gulluni F., Campa C.C., Martini M., Hirsch E. Targeting PI3K signaling in cancer: Challenges and advances. Biochim. Biophys. Acta Rev. Cancer. 2019;1871:361&#x2013;366. doi: 10.1016/j.bbcan.2019.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbcan.2019.03.003</ArticleId><ArticleId IdType="pubmed">30946868</ArticleId></ArticleIdList></Reference><Reference><Citation>Busaidy N.L., Farooki A., Dowlati A., Perentesis J.P., Dancey J.E., Doyle L.A., Brell J.M., Siu L.L. Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J. Clin. Oncol. 2012;30:2919&#x2013;2928. doi: 10.1200/JCO.2011.39.7356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2011.39.7356</ArticleId><ArticleId IdType="pmc">PMC3410405</ArticleId><ArticleId IdType="pubmed">22778315</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W., Qiu Y., Kong D. Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy. Acta Pharm. Sin. B. 2017;7:27&#x2013;37. doi: 10.1016/j.apsb.2016.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2016.07.006</ArticleId><ArticleId IdType="pmc">PMC5237710</ArticleId><ArticleId IdType="pubmed">28119806</ArticleId></ArticleIdList></Reference><Reference><Citation>Palma G., Pasqua T., Silvestri G., Rocca C., Gualtieri P., Barbieri A., De Bartolo A., De Lorenzo A., Angelone T., Avolio E., et al. PI3K&#x3b4; Inhibition as a Potential Therapeutic Target in COVID-19. Front. Immunol. 2020;11:2094. doi: 10.3389/fimmu.2020.02094.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.02094</ArticleId><ArticleId IdType="pmc">PMC7472874</ArticleId><ArticleId IdType="pubmed">32973818</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Eid R., Ward F.J. Targeting the PI3K/Akt/mTOR pathway: A therapeutic strategy in COVID-19 patients. Immunol. Lett. 2021;240:1&#x2013;8. doi: 10.1016/j.imlet.2021.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imlet.2021.09.005</ArticleId><ArticleId IdType="pmc">PMC8457906</ArticleId><ArticleId IdType="pubmed">34562551</ArticleId></ArticleIdList></Reference><Reference><Citation>El Bairi K., Trapani D., Petrillo A., Le Page C., Zbakh H., Daniele B., Belbaraka R., Curigliano G., Afqir S. Repurposing anticancer drugs for the management of COVID-19. Eur. J. Cancer. 2020;141:40&#x2013;61. doi: 10.1016/j.ejca.2020.09.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejca.2020.09.014</ArticleId><ArticleId IdType="pmc">PMC7508523</ArticleId><ArticleId IdType="pubmed">33125946</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanhaesebroeck B., Guillermet-Guibert J., Graupera M., Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat. Rev. Mol. Cell Biol. 2010;11:329&#x2013;341. doi: 10.1038/nrm2882.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm2882</ArticleId><ArticleId IdType="pubmed">20379207</ArticleId></ArticleIdList></Reference><Reference><Citation>Fahy W.A., Homayoun-Valiani F., Cahn A., Robertson J., Templeton A., Meeraus W.H., Wilson R., Lowings M., Marotti M., West S.L., et al. Nemiralisib in Patients with an Acute Exacerbation of COPD: Placebo-Controlled, Dose-Ranging Study. Int. J. Chron. Obstruct. Pulmon. Dis. 2021;16:1637&#x2013;1646. doi: 10.2147/COPD.S309320.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/COPD.S309320</ArticleId><ArticleId IdType="pmc">PMC8184152</ArticleId><ArticleId IdType="pubmed">34113095</ArticleId></ArticleIdList></Reference><Reference><Citation>Campa C.C., Silva R.L., Margaria J.P., Pirali T., Mattos M.S., Kraemer L.R., Reis D.C., Grosa G., Copperi F., Dalmarco E.M., et al. Inhalation of the prodrug PI3K inhibitor CL27c improves lung function in asthma and fibrosis. Nat. Commun. 2018;9:5232. doi: 10.1038/s41467-018-07698-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-07698-6</ArticleId><ArticleId IdType="pmc">PMC6290777</ArticleId><ArticleId IdType="pubmed">30542075</ArticleId></ArticleIdList></Reference><Reference><Citation>Horak F., Puri K.D., Steiner B.H., Holes L., Xing G., Zieglmayer P., Zieglmayer R., Lemell P., Yu A. Randomized phase 1 study of the phosphatidylinositol 3-kinase &#x3b4; inhibitor idelalisib in patients with allergic rhinitis. J. Allergy Clin. Immunol. 2016;137:1733&#x2013;1741. doi: 10.1016/j.jaci.2015.12.1313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2015.12.1313</ArticleId><ArticleId IdType="pubmed">26915677</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler D.G., Faia K.L., DiNitto J.P., Ali J.A., White K.F., Brophy E.E., Pink M.M., Proctor J.L., Lussier J., Martin C.M., et al. PI3K-&#x3b4; and PI3K-&#x3b3; inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem. Biol. 2013;20:1364&#x2013;1374. doi: 10.1016/j.chembiol.2013.09.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chembiol.2013.09.017</ArticleId><ArticleId IdType="pubmed">24211136</ArticleId></ArticleIdList></Reference><Reference><Citation>Aeffner F., Bolon B., Davis I.C. Mouse Models of Acute Respiratory Distress Syndrome: A Review of Analytical Approaches, Pathologic Features, and Common Measurements. Toxicol. Pathol. 2015;43:1074&#x2013;1092. doi: 10.1177/0192623315598399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0192623315598399</ArticleId><ArticleId IdType="pubmed">26296628</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu H.S., Liu C.C., Lin J.H., Hsu T.W., Hsu J.W., Su K., Hung S.C. Involvement of ER stress, PI3K/AKT activation, and lung fibroblast proliferation in bleomycin-induced pulmonary fibrosis. Sci. Rep. 2017;7:14272. doi: 10.1038/s41598-017-14612-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-14612-5</ArticleId><ArticleId IdType="pmc">PMC5660192</ArticleId><ArticleId IdType="pubmed">29079731</ArticleId></ArticleIdList></Reference><Reference><Citation>Hettiarachchi S.U., Li Y.H., Roy J., Zhang F., Puchulu-Campanella E., Lindeman S.D., Srinivasarao M., Tsoyi K., Liang X., Ayaub E.A., et al. Targeted inhibition of PI3 kinase/mTOR specifically in fibrotic lung fibroblasts suppresses pulmonary fibrosis in experimental models. Sci. Transl. Med. 2020;12:eaay3724. doi: 10.1126/scitranslmed.aay3724.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aay3724</ArticleId><ArticleId IdType="pubmed">33115948</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercer P.F., Woodcock H.V., Eley J.D., Plat&#xe9; M., Sulikowski M.G., Durrenberger P.F., Franklin L., Nanthakumar C.B., Man Y., Genovese F., et al. Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF. Thorax. 2016;71:701&#x2013;711. doi: 10.1136/thoraxjnl-2015-207429.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2015-207429</ArticleId><ArticleId IdType="pmc">PMC4975851</ArticleId><ArticleId IdType="pubmed">27103349</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukey P.T., Harrison S.A., Yang S., Man Y., Holman B.F., Rashidnasab A., Azzopardi G., Grayer M., Simpson J.K., Bareille P., et al. A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis. Eur. Respir. J. 2019;53:1801992. doi: 10.1183/13993003.01992-2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01992-2018</ArticleId><ArticleId IdType="pubmed">30765508</ArticleId></ArticleIdList></Reference><Reference><Citation>Madala S.K., Edukulla R., Phatak M., Schmidt S., Davidson C., Acciani T.H., Korfhagen T.R., Medvedovic M., Lecras T.D., Wagner K., et al. Dual targeting of MEK and PI3K pathways attenuates established and progressive pulmonary fibrosis. PLoS ONE. 2014;9:e86536. doi: 10.1371/journal.pone.0086536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0086536</ArticleId><ArticleId IdType="pmc">PMC3903543</ArticleId><ArticleId IdType="pubmed">24475138</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X.L., Xing R.G., Chen L., Liu C.R., Miao Z.G. PI3K/Akt signaling is involved in the pathogenesis of bleomycin-induced pulmonary fibrosis via regulation of epithelial-mesenchymal transition. Mol. Med. Rep. 2016;14:5699&#x2013;5706. doi: 10.3892/mmr.2016.5960.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2016.5960</ArticleId><ArticleId IdType="pubmed">27878273</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian W., Cai X., Qian Q., Zhang W., Wang D. Astragaloside IV modulates TGF-&#x3b2;1-dependent epithelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. J. Cell. Mol. Med. 2018;22:4354&#x2013;4365. doi: 10.1111/jcmm.13725.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.13725</ArticleId><ArticleId IdType="pmc">PMC6111865</ArticleId><ArticleId IdType="pubmed">29971947</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J., Tong X., Zhang L., Zhang Y., Wang L., Wang D., Zhang S., Fan H. Hyperoside Attenuates Bleomycin-Induced Pulmonary Fibrosis Development in Mice. Front. Pharmacol. 2020;11:550955. doi: 10.3389/fphar.2020.550955.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.550955</ArticleId><ArticleId IdType="pmc">PMC7642689</ArticleId><ArticleId IdType="pubmed">33192501</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M.W., Su M.X., Tang D.Y., Hao L., Xun X.H., Huang Y.Q. Ligustrazin increases lung cell autophagy and ameliorates paraquat-induced pulmonary fibrosis by inhibiting PI3K/Akt/mTOR and hedgehog signalling via increasing miR-193a expression. BMC Pulm. Med. 2019;19:35. doi: 10.1186/s12890-019-0799-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12890-019-0799-5</ArticleId><ArticleId IdType="pmc">PMC6371511</ArticleId><ArticleId IdType="pubmed">30744607</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin S., Jin J., Liu Y., Tian H., Zhang Y., Fu R., Zhang J., Wang M., Du T., Ji M., et al. Discovery of 4-Methylquinazoline Based PI3K Inhibitors for the Potential Treatment of Idiopathic Pulmonary Fibrosis. J. Med. Chem. 2019;62:8873&#x2013;8879. doi: 10.1021/acs.jmedchem.9b00969.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.9b00969</ArticleId><ArticleId IdType="pubmed">31335136</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim W.Y., Hong S.B. Sepsis and Acute Respiratory Distress Syndrome: Recent Update. Tuberc. Respir. Dis. 2016;79:53&#x2013;57. doi: 10.4046/trd.2016.79.2.53.</Citation><ArticleIdList><ArticleId IdType="doi">10.4046/trd.2016.79.2.53</ArticleId><ArticleId IdType="pmc">PMC4823184</ArticleId><ArticleId IdType="pubmed">27066082</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>